NEWS RELEASE 06.07.2026 Arrow

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

NEWS RELEASE 06.04.2026 Arrow

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 06.03.2026 Arrow

AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

NEWS RELEASE 06.01.2026 Arrow

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

NEWS RELEASE 05.29.2026 Arrow

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 05.19.2026 Arrow

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

NEWS RELEASE 05.07.2026 Arrow

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 05.04.2026 Arrow

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR

NEWS RELEASE 04.30.2026 Arrow

AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

NEWS RELEASE 04.24.2026 Arrow

AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS

NEWS RELEASE 04.22.2026 Arrow

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

NEWS RELEASE 04.06.2026 Arrow

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

NEWS RELEASE 03.28.2026 Arrow

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

NEWS RELEASE 03.05.2026 Arrow

AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 03.04.2026 Arrow

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

NEWS RELEASE 02.24.2026 Arrow

AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

NEWS RELEASE 02.13.2026 Arrow

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

NEWS RELEASE 02.12.2026 Arrow

EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS

NEWS RELEASE 02.03.2026 Arrow

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

NEWS RELEASE 01.28.2026 Arrow

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

NEWS RELEASE 01.07.2026 Arrow

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

NEWS RELEASE 01.06.2026 Arrow

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Earnings

Show all
ALL RESULTS 

Data as of:

Minimum 15 minutes delayed. Source: LSEG

MORE STOCK